Precigen Explained

Precigen, Inc.
Industry:Biotechnology
Traded As:NASDAQ:
Russell 2000 Component
Predecessors:-->
Successors:-->
Founders:-->
Hq Location City:Germantown, Maryland
Hq Location Country:US
Areas Served:-->
Owners:-->
Num Employees:600
Revenue: $91 million (2019)[1]

Precigen, Inc. (formerly Intrexon Corporation, NASDAQ: PGEN) is an American biotechnology company. Its president and CEO is Helen Sabzevari.

Intrexon was founded in 1998, and is headquartered in Germantown, Maryland.[2] [3] With a suite of proprietary and complementary technologies, Intrexon applies engineering to biological systems to enable DNA-based control over the function and output of living cells.[4]

History

In 2015, Intrexon purchased Oxitec, a maker of genetically sterile insects, for $160 million.[5] In April 2019, Intrexon formed a subsidiary called Precigen, with a focus on human gene therapy. Precigen went on to win orphan drug status from the FDA for a CAR-T based therapy (investigational drug name PRGN-3006) to treat acute myeloid leukemia.[6] [7] In early 2020, Intrexon adopted the name of its subsidiary, Precigen, and narrowed its focus to human gene editing.[8] [9] With the change in name the CEO of subsidiary Precigen, Helen Sabzevari, took over leadership of the company from Randal J. Kirk.[7]

See also

Notes and References

  1. Web site: Precigen Revenue 2012-2021 | PGEN.
  2. Web site: Intrexon Corporation: Private Company Information . Bloomberg . 2017-06-26.
  3. Web site: Intrexon Corp (XON) Company Profile . Reuters.com . 2017-06-26.
  4. News: FAQ Intrexon. Intrexon InvestorRoom. 2018-03-28. en.
  5. News: Market turbulence or not, North American investors plow into farm tech. Nickel. Rod. 15 September 2015. Reuters. 9 October 2015.
  6. Web site: PRGN-3006 Adoptive Cellular Therapy Relapsed or Refractory AML or High Risk MDS. FDA. 6 April 2020.
  7. News: Gilgore. Sara. 6 January 2020. Intrexon will take the name of its subsidiary. That company just scored orphan status for a rare cancer drug.. American City Business Journals. 6 April 2020.
  8. Web site: INTREXON CORPORATION IS NOW PRECIGEN, INC. Precigen. 6 April 2020.
  9. News: Helmstetter. Michael. 30 March 2020. The Promise And Fear Of Gene Editing. Forbes. 6 April 2020.